TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+1.62%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.38B
AUM Growth
+$2.38B
(+1.4%)
Cap. Flow
+$234K
Cap. Flow
% of AUM
0.01%
Top 10 Holdings %
Top 10 Hldgs %
40.59%
Holding
153
New
10
Increased
26
Reduced
19
Closed
10
Top Buys
| 1 |
Abbott
ABT
|
$37.5M |
| 2 |
Cencora
COR
|
$29.9M |
| 3 |
CVS Health
CVS
|
$21.4M |
| 4 |
Neurocrine Biosciences
NBIX
|
$20.7M |
| 5 |
Gilead Sciences
GILD
|
$15.1M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$34.4M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
$24.8M |
| 3 |
Novo Nordisk
NVO
|
$16M |
| 4 |
Ventas
VTR
|
$15.8M |
| 5 |
DOC
PHYSICIANS REALTY TRUST
DOC
|
$14.7M |
Sector Composition
| 1 | Healthcare | 88.83% |
| 2 | Real Estate | 2.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$140B
| $210M | 8.55% | 2,511,731 +180,500 | +8% | +$15.1M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $138M | 5.63% | 1,398,789 -348,445 | -20% | -$34.4M |
|
3
Biogen
BIIB
$19.4B
| $109M | 4.45% | 450,533 | – | – |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $107M | 4.38% | 463,886 +54,300 | +13% | +$12.5M |
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $88.9M | 3.63% | 1,033,503 | – | – |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $79.6M | 3.25% | 681,805 +45,000 | +7% | +$5.25M |
|
7
Incyte
INCY
$16.5B
| $70.4M | 2.87% | 880,461 -76,000 | -8% | -$6.08M |
|
8
Medtronic
MDT
$119B
| $59.3M | 2.42% | 683,704 +126,600 | +23% | +$11M |
|
9
Regeneron Pharmaceuticals
REGN
$61.5B
| $53.9M | 2.2% | 154,266 | – | – |
|
10
Pfizer
PFE
$141B
| $52.2M | 2.13% | 1,483,291 -328,720 | -18% | -$11.6M |
|
11
Illumina
ILMN
$15.8B
| $52.1M | 2.13% | 371,364 +22,500 | +6% | +$3.16M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $50.9M | 2.08% | 653,845 +57,700 | +10% | +$4.49M |
|
13
Amgen
AMGN
$155B
| $50.5M | 2.06% | 331,740 +10,100 | +3% | +$1.54M |
|
14
UnitedHealth
UNH
$281B
| $46.8M | 1.91% | 331,100 -78,000 | -19% | -$11M |
|
15
Merck
MRK
$210B
| $46M | 1.88% | 797,597 +116,500 | +17% | +$6.71M |
|
16
Johnson & Johnson
JNJ
$427B
| $40.9M | 1.67% | 337,312 -37,776 | -10% | -$4.58M |
|
17
Eli Lilly
LLY
$657B
| $39.6M | 1.62% | 502,567 +85,400 | +20% | +$6.73M |
|
|
18
Abbott
ABT
$231B
| $37.5M | 1.53% | +953,500 | New | +$37.5M |
|
|
SHPG
19
DELISTED
Shire pic
SHPG
| $37.1M | 1.52% | 201,713 | – | – |
|
|
20
Neurocrine Biosciences
NBIX
$13.8B
| $34.9M | 1.42% | 767,022 +455,562 | +146% | +$20.7M |
|
21
Teva Pharmaceuticals
TEVA
$21.1B
| $33.8M | 1.38% | 671,958 | – | – |
|
22
Viatris
VTRS
$12.3B
| $31.2M | 1.28% | 722,552 +104,600 | +17% | +$4.52M |
|
23
Alkermes
ALKS
$4.78B
| $30M | 1.22% | 693,844 +111,900 | +19% | +$4.84M |
|
|
24
Cencora
COR
$56.5B
| $29.9M | 1.22% | +376,500 | New | +$29.9M |
|
25
Molina Healthcare
MOH
$9.8B
| $26.8M | 1.1% | 537,901 +190,000 | +55% | +$9.48M |
|